Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability.
about
The impact of citrate introduction at UK syringe exchange programmes: a retrospective cohort study in Cheshire and Merseyside, UKTake home naloxone and the prevention of deaths from opiate overdose: two pilot schemesNaloxone distribution and cardiopulmonary resuscitation training for injection drug users to prevent heroin overdose death: a pilot intervention studyPhysicians' knowledge of and willingness to prescribe naloxone to reverse accidental opiate overdose: challenges and opportunitiesDifferent forms of heroin and their relationship to cook-up techniques: data on, and explanation of, use of lemon juice and other acidsOverdose experiences among injection drug users in Bangkok, ThailandEvaluation of a naloxone distribution and administration program in New York City.Evaluation of an overdose prevention and response training programme for injection drug users in the Skid Row area of Los Angeles, CA.Opiate users' knowledge about overdose prevention and naloxone in New York City: a focus group study.Strategies for preventing heroin overdose.Homeless drug users' awareness and risk perception of peer "take home naloxone" use--a qualitative studyDistinguishing signs of opioid overdose and indication for naloxone: an evaluation of six overdose training and naloxone distribution programs in the United States.Overdose prevention for injection drug users: lessons learned from naloxone training and distribution programs in New York City.A Review of Opioid Overdose Prevention and Naloxone Prescribing: Implications for Translating Community Programming Into Clinical Practice.Attitudes and knowledge about naloxone and overdose prevention among detained drug users in Ningbo, China.Prevalence and correlates of opiate overdose among young injection drug users in a large U.S. cityPreliminary evidence of health care provider support for naloxone prescription as overdose fatality prevention strategy in New York City.Attitudes about prescribing take-home naloxone to injection drug users for the management of heroin overdose: a survey of street-recruited injectors in the San Francisco Bay AreaFatal heroin-related overdose in San Francisco, 1997-2000: a case for targeted intervention.Attitudes of Emergency Medical Service providers towards naloxone distribution programs.Attitudes of Australian heroin users to peer distribution of naloxone for heroin overdose: perspectives on intranasal administrationHigh uptake of naloxone-based overdose prevention training among previously incarcerated syringe-exchange program participants.Naloxone treatment in opioid addiction: the risks and benefits.Personal social network factors associated with overdose prevention training participationDosage patterns in methadone treatment: results from a national survey, 1988-2005.Take-home emergency naloxone to prevent heroin overdose deaths after prison release: rationale and practicalities for the N-ALIVE randomized trial.Randomized controlled pilot trial of naloxone-on-release to prevent post-prison opioid overdose deathsHeroin uncertainties: Exploring users' perceptions of fentanyl-adulterated and -substituted 'heroin'.Drug users' experiences of witnessing overdoses: what do they know and what do they need to know?Assessing causality in drug policy analyses: How useful are the Bradford Hill criteria in analysing take-home naloxone programs?Patient perspectives on an opioid overdose education and naloxone distribution program in the U.S. Department of Veterans Affairs.Patient Simulation for Assessment of Layperson Management of Opioid Overdose With Intranasal Naloxone in a Recently Released Prisoner Cohort.Engagement in a National Naloxone Programme among people who inject drugs.Awareness, Possession, and Use of Take-Home Naloxone Among Illicit Drug Users, Vancouver, British Columbia, 2014-2015.Scotland's national naloxone program: The prison experience.Attitudes Toward Naloxone Prescribing in Clinical Settings: A Qualitative Study of Patients Prescribed High Dose Opioids for Chronic Non-Cancer Pain.Death matters: understanding heroin/opiate overdose risk and testing potential to prevent deaths.2017 HIVMA of IDSA Clinical Practice Guideline for the Management of Chronic Pain in Patients Living With HIV.Expanding access to naloxone in the United States.Neurochemical Markers in the Mammalian Brain: Structure, Roles in Synaptic Communication, and Pharmacological Relevance.
P2860
Q21245631-6A9732ED-85E4-40FE-AF9E-6D857165D7ECQ24596414-4E628FD3-7FE5-4A44-9BA9-49E6321F559EQ24650146-E31D83BD-A16D-4C7A-94C4-093CA165A0E1Q24678034-F92711E1-E5CE-4832-9386-5F6739B57408Q28203041-793BF262-987D-4F7D-A27E-89C2C5B4A8CCQ33892468-6585BE2F-C7FC-4CFB-89A9-EA849A037E87Q34788017-726717BE-7723-46DF-9B13-3D7923880A54Q34923675-E05DB6F3-0BDF-4DDE-8E11-FECCC405E091Q35012003-33CBACC8-904E-41BE-88C4-84E4D698C763Q35069474-1FFE6FB9-E15C-461B-82F1-322787B67469Q35079876-F70A6929-B07E-4495-8F2B-172F475CBFD1Q35186225-18B219E3-C45B-4F98-961A-4AE36A35D0DBQ35633605-AA8E108F-A790-451E-9D55-4A1C2EB4933DQ35751870-3FAC3337-2CF9-4EA4-BCBD-CAC0BFFE03FEQ35808935-8699434A-F33F-4DBA-B99B-7210B355A0A0Q35946118-183FB4EE-323A-48B3-932A-D4915EF4A104Q36273558-FE304F05-3F06-42D9-AAA0-F2B3D9851700Q36273617-CA8773B8-BE7A-4563-8820-508CF7E54F27Q36273622-453EBC37-A77E-4589-9766-477D7142E51CQ36274283-6197C284-7A7F-4E61-834C-18CB3E4C16C6Q36579537-06298148-C95B-49F9-932C-100B2700B8C5Q36728346-B78623A4-2889-4206-B2BB-8561B3111A35Q36762428-EB7DA2AB-75ED-496B-B894-F568ED33BB65Q36974799-B969AE94-D520-450F-8BBA-BC367498062DQ37037332-70177EBF-1776-4EF5-A9F7-5CA7B9F8FB22Q37225942-2AFB626F-E291-45B8-8FE8-16A9E88837E3Q37664252-0A79C9ED-C97A-48B6-A964-DE5A9BBAFE90Q38429650-84C38D6C-4F00-433A-B449-0C7C9150F541Q38687523-15F9AB5D-DA61-4265-9BF6-F12E87BC4EA6Q38831012-55EBC71B-BF36-4DDF-B94A-5C4B1D3E693EQ38931214-BD89954D-60BD-47BC-8853-5D1A540E52E7Q38986529-06A85EE2-B5D2-49F4-AE07-57F60420CC09Q39930793-C1E4616E-181C-4201-A706-2B12C3C18BD2Q40116883-80A20696-036D-4967-8C4E-91D7D2B11DF5Q40248801-D150C004-82DF-4206-A19D-4CEF0BD9CF99Q40502695-4C2A0381-5869-4126-AFEE-A9C0E83F8022Q40870164-C1905F74-5FCF-4D53-AE2A-C08DD2495142Q41919082-8D50CB24-4627-4E61-8EB5-EAF27CA63BDDQ41982971-A6FCB06B-95CA-449F-A5CD-CD73C4D2DB5FQ42380034-B0AB4CDD-CB53-44D2-8E4B-163812DF100D
P2860
Preventing opiate overdose fatalities with take-home naloxone: pre-launch study of possible impact and acceptability.
description
1999 nî lūn-bûn
@nan
1999 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1999 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1999年の論文
@ja
1999年論文
@yue
1999年論文
@zh-hant
1999年論文
@zh-hk
1999年論文
@zh-mo
1999年論文
@zh-tw
1999年论文
@wuu
name
Preventing opiate overdose fat ...... ible impact and acceptability.
@ast
Preventing opiate overdose fat ...... ible impact and acceptability.
@en
type
label
Preventing opiate overdose fat ...... ible impact and acceptability.
@ast
Preventing opiate overdose fat ...... ible impact and acceptability.
@en
prefLabel
Preventing opiate overdose fat ...... ible impact and acceptability.
@ast
Preventing opiate overdose fat ...... ible impact and acceptability.
@en
P2093
P1433
P1476
Preventing opiate overdose fat ...... ible impact and acceptability.
@en
P2093
Griffiths P
P304
P356
10.1046/J.1360-0443.1999.9421993.X
P407
P577
1999-02-01T00:00:00Z